Evidence map›Paper›PMID 40172351›Full record

ArticleRevista brasileira de enfermagem2025

Outcome measures reported by cancer patients treated with tyrosine kinase inhibitors: a methodological study.

Ana Maria Teixeira Pires, Julie Ann Ponto, Eliana Cavalari Teraoka, Fabio Rodrigues Kerbauy, Edvane Birelo Lopes De Domenico

Abstract read
In one paragraph

Article in Revista brasileira de enfermagem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ana Maria Teixeira PiresUniversidade Federal de São Paulo. São Paulo, São Paulo, Brazil.ORCID 0000-0003-4666-1122
Julie Ann PontoWinona State University. Rochester, Minessota, United States of America.ORCID 0009-0002-4294-7916
Eliana Cavalari TeraokaUniversidade Federal de São Paulo. São Paulo, São Paulo, Brazil.ORCID 0000-0001-8865-8031
Fabio Rodrigues KerbauyUniversidade Federal de São Paulo. São Paulo, São Paulo, Brazil.ORCID 0000-0002-2819-2783
Edvane Birelo Lopes De DomenicoUniversidade Federal de São Paulo. São Paulo, São Paulo, Brazil.ORCID 0000-0001-7455-1727

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesto validate the content of an outcome measurement instrument with expert judges and to assess the understandability and suitability of this validated instrument with cancer patients undergoing tyrosine kinase inhibitor (TKI) therapy.

methodsa methodological study, which included the development of an instrument through integrative review, content validity, using the Delphi technique with expert judges, and pilot testing, to verify users' understandability and suitability to the instrument.

resultsliterature review allowed constructing PRO-CTCAE® Estudo PROM-TKI Brasil, with 16 items, which was later submitted to validity using the Delphi technique. After the second round, the final instrument consisted of 20 items, with a Content Validity Index (CVI) of 0.878. The pilot test showed that the instrument is understandable and suitable for the target population (CVI of 1.0).

conclusionsPRO-CTCAE® Estudo PROM-TKI Brasil obtained evidence of validity for use during TKI therapy.

Indexed as

NeoplasmsOutcome Assessment, Health CarePatient Reported Outcome MeasuresProtein Kinase InhibitorsBrazilDelphi TechniqueHumansMaleProtein-Tyrosine KinasesPsychometricsReproducibility of ResultsSurveys and QuestionnairesTyrosine Kinase InhibitorsProtein Kinase InhibitorsProtein-Tyrosine KinasesTyrosine Kinase Inhibitors

Identifiers

PMID40172351
PMCPMC11961046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.